These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 34168967)

  • 1. How do serotonergic psychedelics treat depression: The potential role of neuroplasticity.
    Artin H; Zisook S; Ramanathan D
    World J Psychiatry; 2021 Jun; 11(6):201-214. PubMed ID: 34168967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants.
    Kadriu B; Greenwald M; Henter ID; Gilbert JR; Kraus C; Park LT; Zarate CA
    Int J Neuropsychopharmacol; 2021 Jan; 24(1):8-21. PubMed ID: 33252694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics.
    de Vos CMH; Mason NL; Kuypers KPC
    Front Psychiatry; 2021; 12():724606. PubMed ID: 34566723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action?
    Husain MI; Ledwos N; Fellows E; Baer J; Rosenblat JD; Blumberger DM; Mulsant BH; Castle DJ
    Front Psychiatry; 2022; 13():1076459. PubMed ID: 36844032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Potential Role of Serotonergic Hallucinogens in Depression Treatment.
    Psiuk D; Nowak E; Cholewa K; Łopuszańska U; Samardakiewicz M
    Life (Basel); 2021 Jul; 11(8):. PubMed ID: 34440508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.
    Galvão-Coelho NL; Marx W; Gonzalez M; Sinclair J; de Manincor M; Perkins D; Sarris J
    Psychopharmacology (Berl); 2021 Feb; 238(2):341-354. PubMed ID: 33427944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives.
    Pallavicini C; Vilas MG; Villarreal M; Zamberlan F; Muthukumaraswamy S; Nutt D; Carhart-Harris R; Tagliazucchi E
    Neuroimage; 2019 Oct; 200():281-291. PubMed ID: 31247301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential of psychedelics for the treatment of Alzheimer's disease and related dementias.
    Winkelman MJ; Szabo A; Frecska E
    Eur Neuropsychopharmacol; 2023 Nov; 76():3-16. PubMed ID: 37451163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are "mystical experiences" essential for antidepressant actions of ketamine and the classic psychedelics?
    Hashimoto K
    Eur Arch Psychiatry Clin Neurosci; 2024 Feb; ():. PubMed ID: 38411629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Dendrite-Focused Framework for Understanding the Actions of Ketamine and Psychedelics.
    Savalia NK; Shao LX; Kwan AC
    Trends Neurosci; 2021 Apr; 44(4):260-275. PubMed ID: 33358035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbiota-derived psychedelics: Lessons from COVID-19.
    Sfera A; Hazan S; Kozlakidis Z; Klein C
    Adv Clin Exp Med; 2023 Apr; 32(4):395-399. PubMed ID: 36753370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.
    Johnson MW; Hendricks PS; Barrett FS; Griffiths RR
    Pharmacol Ther; 2019 May; 197():83-102. PubMed ID: 30521880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addiction specialists' attitudes toward psychedelics: A National Survey.
    Kim A; Suzuki J
    Am J Addict; 2023 Nov; 32(6):606-609. PubMed ID: 37550848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression.
    Hibicke M; Landry AN; Kramer HM; Talman ZK; Nichols CD
    ACS Chem Neurosci; 2020 Mar; 11(6):864-871. PubMed ID: 32133835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer.
    Dos Santos RG; Bouso JC; Hallak JEC
    BMC Psychiatry; 2019 Oct; 19(1):321. PubMed ID: 31660905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total Recall: Lateral Habenula and Psychedelics in the Study of Depression and Comorbid Brain Disorders.
    Vitkauskas M; Mathuru AS
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32906643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics.
    Schindler EAD; Wallace RM; Sloshower JA; D'Souza DC
    Front Pharmacol; 2018; 9():177. PubMed ID: 29545753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroplasticity and depression: Rewiring the brain's networks through pharmacological therapy (Review).
    Rădulescu I; Drăgoi AM; Trifu SC; Cristea MB
    Exp Ther Med; 2021 Oct; 22(4):1131. PubMed ID: 34504581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression.
    Davis R; Wilde MI
    CNS Drugs; 1996 May; 5(5):389-402. PubMed ID: 26071050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond the serotonin deficit hypothesis: communicating a neuroplasticity framework of major depressive disorder.
    Page CE; Epperson CN; Novick AM; Duffy KA; Thompson SM
    Mol Psychiatry; 2024 May; ():. PubMed ID: 38816586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.